Last update June 7, 2020
Very Low Risk
This is a immune-response modifier, used in the local treatment of genital and perianal warts, cutaneous basal cell tumors and actinic keratosis.
Administered topically, once a day or every two days for several weeks, according to pathology.
Since the last update we have not found any published data on its excretion in breastmilk.
The cutaneous absorption to the patient's blood is extremely low: 0.6% with a Cmax of 0.32 to 1.6 ng/mL (EMA 2016, Wu 2012, Kulp 2010, Harrison 2004, FDA 2004), which makes it very unlikely that there is transfer in significant amounts to breastmilk.
It is used in the topical treatment of infantile hemangiomas from a month of life (Satterfield 2019, Craiglow 2013, Ho 2007).
As with any product applied to the skin, it is prudent to avoid its use in areas near the breast and nipple so that there is no risk of swallowing by the infant.
We do not have alternatives for Imiquimod since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM